IMNM
IMNM
NASDAQ · Biotechnology

Immunome Inc

$18.60
+0.70 (+3.88%)
As of Nov 7, 1:36 AM ET ·
Financial Highlights (FY 2026)
Revenue
9.47M
Net Income
-289,778,417
Gross Margin
—
Profit Margin
-3,060.0%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — 51.0% 51.0% 51.0%
Operating Margin -3,228.8% -33.8% -27.1% -32.6%
Profit Margin -3,060.0% -28.7% -29.6% -28.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 9.47M 603.96M 550.96M 661.77M
Gross Profit — 308.25M 281.20M 337.76M
Operating Income -305,917,306 -204,125,859 -149,200,100 -215,700,821
Net Income -289,778,417 -173,219,826 -162,867,502 -187,119,094
Gross Margin — 51.0% 51.0% 51.0%
Operating Margin -3,228.8% -33.8% -27.1% -32.6%
Profit Margin -3,060.0% -28.7% -29.6% -28.3%
Rev Growth — +13.0% +19.7% +11.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 349.67M 358.31M 392.24M
Total Equity — 1.78B 1.86B 1.97B
D/E Ratio — 0.20 0.19 0.20
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -302,399,242 -273,358,868 -247,027,649 -323,672,786
Free Cash Flow — -130,399,233 -192,377,550 -194,010,121